Skip to main navigation
Akero
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Our History
    • Leadership
    • Contact
  • Focus
    • Therapeutic Areas
    • Publications & Posters
  • Pipeline
    • Development Pipeline
    • Efruxifermin (EFX)
    • Research Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access Policy
  • Careers
    • Our Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
Select Page
Akero
    • About
      • Our Company
      • Our History
      • Leadership
      • Contact
    • Focus
      • Therapeutic Areas
      • Publications & Posters
    • Pipeline
      • Development Pipeline
      • Efruxifermin (EFX)
      • Research Programs
    • Clinical Trials
      • Clinical Trials Overview
      • Expanded Access Policy
    • Careers
      • Our Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historic Price Lookup
        • Analyst Coverage
      • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
        • Committee Composition
      • Investor Resources
        • Investor FAQs
        • Investor Email Alerts
        • Contact IR
    • Linked
    • Twitter
Hero-banner

SEC Filing Details

Hero-banner

Document Details

Form
10-K
Filing Date
Feb 25, 2022
Document Date
Dec 31, 2021
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Akero Therapeutics, Inc.
Issuer
Akero Therapeutics, Inc.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - EX-101.CAL
EX-101.DEF - EX-101.DEF
EX-101.LAB - EX-101.LAB
EX-101.PRE - EX-101.PRE
XML - XBRL INSTANCE DOCUMENT
  • About
  • Our Company
  • Our History
  • Leadership
  • Contact
  • Focus
  • Therapeutic Areas
  • Publications & Posters
  • Pipeline
  • Development Pipeline
  • Efruxifermin (EFX)
  • Research Programs
  • Clinical Trials
  • Clinical Trials Overview
  • Expanded Access Policy
  • Careers
  • Our Culture
  • Job Opportunities
  • Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor Resources
Footer logo
©2021 Akero Therapeutics, Inc.
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter